Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 20/20 | 0.59 |
| ▸ | KDR | P35968 | 19/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 16/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 16/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 16/20 | 0.50 |
| ▸ | FLT3 | P36888 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7601941 | 0.84 | LPL (0.47) | KDRFLT3 | |
| SCHEMBL20074518 | 0.79 | ACVR1B (0.42) | FGFR3KDR | |
| SCHEMBL15747741 | 0.79 | DGAT1 (0.50) | FGFR3KDR | |
| SCHEMBL30434548 | 0.79 | DGAT1 (0.50) | FGFR3KDR | |
| SCHEMBL7603285 | 0.79 | LPL (0.47) | KDRFLT3 | |
| SCHEMBL1817315 | 0.77 | IRAK4 (0.47) | — | |
| SCHEMBL17544370 | 0.77 | MET (0.42) | — | |
| SCHEMBL31503579 | 0.77 | TLR9 (0.52) | KDRFLT3 | |
| SCHEMBL16257036 | 0.76 | FGFR3 (0.72) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL15109046 | 0.76 | LPL (0.44) | KDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856236-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2018-01-02 | — | — | US | disclosed |
| US-9290478-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-03-22 | — | — | US | disclosed |
| US-9290478-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-03-22 | — | — | US | disclosed |
| US-20160031856-A1 | SUBSTITUTED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2016-02-04 | — | — | US | disclosed |
| US-20160031856-A1 | SUBSTITUTED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2016-02-04 | — | — | US | disclosed |
| US-9145394-B2 | — | — | 2015-09-29 | — | — | US | disclosed |
| US-9145394-B2 | — | — | 2015-09-29 | — | — | US | disclosed |
| EP-2646432-B1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | ASTEX THERAPEUTICS LTD (GB) | 2015-04-08 | — | — | EP | disclosed |
| US-20130267525-A1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267525-A1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| EP-2173354-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-04-14 | — | — | EP | disclosed |
| EP-2150255-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | Smithkline Beecham Corporation (US) | 2010-02-10 | — | — | EP | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2009021083-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008141065-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | FGFR3 2690/4885KDR 1697/4885FGFR1 2999/4885 |
| US-20160031856-A1 | SUBSTITUTED QUINOXALINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR3, ABL1 | FGFR3 2/4885KDR 64/4885FGFR1 1/4885 |
| US-20130267525-A1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | FGFR1, FGFR4, FGFR3 | FGFR3 3/4885KDR 105/4885FGFR1 1/4885 |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | FGFR3 2690/4885KDR 1697/4885FGFR1 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.